NCT06489548View on ClinicalTrials.gov

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
DementiaAlzheimers DiseaseMild Cognitive Impairment Due to Alzheimer's Disease
Interventions
DRUG

Foralumab TZLS-401 50 µg

Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 50 µg vs. placebo.

DRUG

Foralumab TZLS-401 100 µg

Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 100 µg vs. placebo.

Trial Locations (1)

02115

Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Tiziana Life Sciences LTD

INDUSTRY

lead

Brigham and Women's Hospital

OTHER